Page 17 - Aurobindo Pharma

Growth in key markets perks up Aurobindo stock, earnings to increase

On the flip side, Aurobindo may have seen some pressure on margins led by one-offs as product recall/provisions and some impact on higher raw-material prices

Aurobindo Pharma Q1 net profit slips 12% to Rs 4.5 bn over rising expenses

Total expenses of the company for the first quarter were Rs 37.23 billion, compared to Rs 29.92 billion in the same period last fiscal

Apotex acquisition likely to reduce Aurobindo's dependence on US market

The Apotex acquisition will further strengthen Aurobindo's position among the top 10 pharma companies by sales in Europe

Apotex buy may not initially contribute to Aurobindo's earnings

Unlikely to add to profits in first 2 years; working capital may rise

Aurobindo pharma likely to clinch Mallinckrodt deal for $800 mn this July

Street cautious as Mallinckrodt biz is declining amid enhanced scrutiny on opioid drugs

Aurobindo Pharma gets USFDA nod for pain reliever Ibuprofen; launch in Sept

Quoting Nielsen data, Aurobindo Pharma said the estimated market size of ibuprofen capsules OTC is $164 million for the twelve months ending March 2018

Aurobindo Pharma: Nod for niche drugs, strong pipeline to push earnings

Analysts at Elara Capital say Ertapenem approval gives comfort to Aurobindo's ability to grow its US business in FY19, despite the high base

Hyderabad's Aurobindo in race to buy Novartis' generic dermatology business

---- Places a non-binding initial bid of $1.6 bn for the US assets ---- Analysts feel Aurobindo's bid is aggressively placed for low margin assets

US FDA finds 'female mosquito' in Aurobindo Pharma's unit during inspection

FDA also observed that Aurobindo Pharma employees lack the training required to perform their assigned functions

Aurobindo Pharma stock: Good growth in Europe may cushion downside

Analysts said given the strong European prospects and as most concerns relating to unit-IV are priced in, downside was limited for the stock

Aurobindo Pharma receives USFDA observations, say reports; stock falls 5%

The stock dipped 5.4% to Rs 590 on the BSE after the media report suggested that the company received nine observations from the US drug regulator for one of its Hyderabad units.

US inspectors cite serious quality issues at Aurobindo Pharma's Unit 4

BS ReporterHyderabad, 4 March: The US Food and Drug Administration(USFDA) has issued Form 483 with 9 observations to Aurobindo Pharma Limited's unit 4 in Hyderabad, citing serious deficiencies in maintaining the manufacturing quality standards. The FDA representatives had inspected the facility between February 12-20, 2018.Located in Pashamailaram industrial estate on the city outskirts, Unit-4 is a dedicated manufacturing facility for generic sterile injectables ( lyophilized and powder injections, prefilled syringes), opthalmics and low volume parenterals.According to the Form 483, a copy of which was reviewed by this reporter, the inspection team has noticed poor maintenance of equipment and premises among other quality issues at the site.The FDA representative also noted that despite alerting the management regarding certain black stains on a filling machine, no action was taken to remove the dirt, which could potentially impact the quality of the drug product."Equipment and ...

Aurobindo Pharma wrests second position among drug firms from Lupin

While Lupin recorded a 10.6 per cent decline in its sales for the period, the largest, Sun Pharma, recorded a 17.4 per cent fall

Aurobindo Pharma Q3 net profit up 2.8% at Rs 5.95 billion

BS ReporterHyderabad, 7 February: Aurobindo Pharma Limited has reported a 2.8 percent increase in consolidated net profit at Rs 5.95 billion for the quarter ended December 2017 as compared to Rs 5.79 billion in the corresponding quarter previous year.The Hyderabad-based generic drug major's revenues grew 11 percent at Rs 43. 36 billion during the quarter under review from Rs 39.06 billion in the year ago period on the back of a rise in formulation sales across the geographies. Particularly, the company's formulation sales in Europe rose 37 percent at Rs 11.72 billion while the same in the US market grew by 9.4 percent to touch Rs 19.1 billion from Rs 17.45 in the corresponding previous quarter.Formulation sales registered an overall growth of 12.2 percent during the quarter under review despite a 30.1 percent fall in anti retro viral(ARV) sales at Rs 2.39 billion during the perriod.Commenting on the company's performance, Aurobindo managing director N Govindarajan said,"All our key ...

Aurobindo Pharma looks for inorganic growth prospects in East Europe

Earlier this year, the company announced acquisition of Portugal's Generis Farmaceutica SA from Magnum Capital Partners for a consideration of Euro 135 mn

Aurobindo Pharma gets USFDA nod for heartburn drug

Aurobindo Pharma said the product will be launched immediately

Aurobindo's new anti-HIV drug may better its anti-retroviral business

BS ReporterHyderabad, 3 October: The dwindling anti-retroviral(ARV) contribution to the overall revenues of Aurobindo Pharma is likely to see improvement in the second half of the current financial year as the company expects to launch its new Dolutegravir(DTG) triple combination drug in the sub-Saharan Africa in the third quarter.In August the company had received tentative approval from the US Food and Drug Administration(USFDA) under the US President's Emergency Plan For AIDS Relief (PEPFAR) for its new drug application for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets. The company is expected to realise the full revenue potential of the product once it gets the final USFDA approval to be able to launch in the US market. Aurobindo considers DTG as the growth driver in the next 3-4 years in ARV segment. According to the company, the triple drug combination product is expected to have a $ 500 million market in 2018. Aurobindo is the first company to sign license .

Aurobindo to widen portfolio in US, enter new European markets in 3-4 years

Besides, it also plans to increase collaboration across the global customer base

Aurobindo bets on Eastern Europe with larger product base, acquisition

BS ReporterHyderabad, 11 August: Aurobindo Pharma Limited is looking at Eastern Europe as a priority market for inorganic growth as it seeks to further expand its European operations, which came as a strong insurance in the face of headwinds from the US market in the form of steep price erosion."We always actively pursue M&A opportunities for the purpose of market penetration and for new product platforms. When it comes to geographical preference Eastern Europe is more attractive in terms of priority," N Govinda Rajan said in response to a question during the analysts call yesterday.The company's acquisition-led strategy has paid off in Europe, which now accounts for 25 percent of Aurobindo's revenues and growing in double digits even at a time US sales stayed flat despite launching more number of new products.The look out for acquisition opportunities in the Eastern Europe comes close on the heals of the completion of Euro 135 million acquisition of Generis Pharmaceutica by its .

Aurobindo Pharma ups the ante in oncology space

Manufacturing of these drugs would commence from 2018-19